Nymox Pharmaceutical Announces NEXUS-1 and NEXUS-2 Phase 3 Trials for NX-1207 Investigational Drug for BPH

November 19, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the NEXUS-1 and NEXUS-2 Phase 3 clinical trials for NX-1207, the Company's new drug for benign prostatic hyperplasia (BPH).

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 3